期刊文献+

Efficacy and safety of rabeprazole in non-steroidal anti-inflammatory drug-induced ulcer in Japan 被引量:9

Efficacy and safety of rabeprazole in non-steroidal anti-inflammatory drug-induced ulcer in Japan
下载PDF
导出
摘要 AIM: To investigate the effi cacy and safety of rabepra-zole under continuous non-steroidal anti-inflammatory drug (NSAID) administration for NSAID-induced ulcer in Japan. METHODS: Subjects comprised patients undergoing NSAID treatment in whom upper gastrointestinal en-doscopy revealed an ulcerous lesion (open ulcer) with diameter ≥ 3 mm, who required continuous NSAID treatment. Endoscopies were performed at the start of treatment, during the treatment period, and at the conclusion (or discontinuation) of treatment. Findings were evaluated as size (maximum diameter) and stage based on the Sakita-Miwa classifi cation. An ulcer was regarded as cured when the "white coating" was seen to have disappeared under endoscopy. As criteria for evaluating safety, all medically untoward symptoms and signs (adverse events, laboratory abnormalities, accidental symptoms, etc.) occurring after the start of rabeprazole treatment were handled as adverse events.RESULTS: Endoscopic cure rate in 38 patients in the efficacy analysis (endoscopic evaluation) was 71.1% (27/38). Among those 38 patients, 35 had gastric ulcer with a cure rate of 71.4% (25/35), and 3 had duodenal ulcer with a cure rate of 66.7% (2/3). Three adverse drug reactions were reported from 64 patients in the safety analysis (interstitial pneumonia, low white blood cell count and pruritus); thus, the incidence rate for adverse drug reactions was 4.7% (3/64).CONCLUSION: The treatment efficacy of rabeprazole for NSAID-induced ulcer under continuous NSAID ad-ministration was confi rmed. AIM: To investigate the effi cacy and safety of rabepra-zole under continuous non-steroidal anti-inflammatory drug (NSAID) administration for NSAID-induced ulcer in Japan. METHODS: Subjects comprised patients undergoing NSAID treatment in whom upper gastrointestinal en-doscopy revealed an ulcerous lesion (open ulcer) with diameter ≥ 3 mm, who required continuous NSAID treatment. Endoscopies were performed at the start of treatment, during the treatment period, and at the conclusion (or discontinuation) of treatment. Findings were evaluated as size (maximum diameter) and stage based on the Sakita-Miwa classifi cation. An ulcer was regarded as cured when the "white coating" was seen to have disappeared under endoscopy. As criteria for evaluating safety, all medically untoward symptoms and signs (adverse events, laboratory abnormalities, accidental symptoms, etc.) occurring after the start of rabeprazole treatment were handled as adverse events.RESULTS: Endoscopic cure rate in 38 patients in the efficacy analysis (endoscopic evaluation) was 71.1% (27/38). Among those 38 patients, 35 had gastric ulcer with a cure rate of 71.4% (25/35), and 3 had duodenal ulcer with a cure rate of 66.7% (2/3). Three adverse drug reactions were reported from 64 patients in the safety analysis (interstitial pneumonia, low white blood cell count and pruritus); thus, the incidence rate for adverse drug reactions was 4.7% (3/64).CONCLUSION: The treatment efficacy of rabeprazole for NSAID-induced ulcer under continuous NSAID ad-ministration was confirmed.
作者 Yuji Mizokami
机构地区 Gamagori City Hospital
出处 《World Journal of Gastroenterology》 SCIE CAS CSCD 2009年第40期5097-5102,共6页 世界胃肠病学杂志(英文版)
  • 相关文献

参考文献30

  • 1Hungin AP,Kean WF.Nonsteroidal anti-inflammatory drugs:overused or underused in osteoarthritis? Am J Med 2001; 110:8S-11S.
  • 2Lichtenstein DR,Syngal S,Wolfe MM.Nonsteroidal antiinflammatory drugs and the gastrointestinal tract.The double-edged sword.Arthritis Rheum 1995; 38:5-18.
  • 3Soll AH,Weinstein WM,Kurata J,McCarthy D.Nonsteroidal anti-inflammatory drugs and peptic ulcer disease.Ann Intern Med 1991; 114:307-319.
  • 4Goldstein JL.Challenges in managing NSAID-associated gastrointestinal tract injury.Digestion 2004; 69 Suppl 1:25-33.
  • 5Larkai EN,Smith JL,Lidsky MD,Graham DY.Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic nonsteroidal anti-inflammatory drug use.Am J Gastroenterol 1987; 82:1153-1158.
  • 6Laine L.Nonsteroidal anti-inflammatory drug gastropathy.Gastrointest Endosc Clin N Am 1996; 6:489-504.
  • 7Singh G.Recent considerations in nonsteroidal antiinflammatory drug gastropathy.Am J Med 1998; 105:31S-38S.
  • 8Bidaut-Russell M,Gabriel SE.Adverse gastrointestinal effects of NSAIDs:consequences and costs.Best Pract Res Clin Gastroenterol 2001; 15:739-753.
  • 9Shiokawa Y,Nobunaga M,Saito T,Asaki S,Ogawa N.Epidemiology study on upper gastrointestinal lesions induced by non-steroidal anti-inflammatory drugs.Ryumachi 1991; 31:96-111.
  • 10Regula J,Butruk E,Dekkers CP,de Boer SY,Raps D,Simon L,Terjung A,Thomas KB,Luhmann R,Fischer R.Prevention of NSAID-associated gastrointestinal lesions:a comparison study pantoprazole versus omeprazole.Am J Gastroenterol 2006; 101:1747-1755.

同被引文献67

引证文献9

二级引证文献57

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部